Novo Nordisk's CagriSema Shows 25% Average Weight Loss in Women with Obesity in Late-Stage Study

Novo Nordisk announced that its experimental next-generation drug, CagriSema, led to an average of 25% weight loss in women with obesity or overweight, according to data analyzed after the completion of a late-stage study. This development positions CagriSema as a potential successor to Wegovy in the rapidly growing weight-loss market.